SCHEDULE 13D/A: General Atlantic Completes Divestment of Third Harmonic Bio Stake, Files Final Exit Amendment
Ownership Change Filing
Investment firm General Atlantic and its affiliated entities have fully divested their beneficial ownership in Third Harmonic Bio, Inc., marking their complete exit as a reportable shareholder.
Summary
- General Atlantic, L.P. and its affiliated entities (the "Reporting Persons") have filed Amendment No. 2 to their Schedule 13D, indicating a complete divestment of their beneficial ownership in Third Harmonic Bio, Inc. (the "Company").
- This amendment serves as the final filing for the Reporting Persons, signifying their exit from a reportable position in the Company's common stock.
- As of the filing date, the Reporting Persons are deemed to beneficially own 0.0% of the Company's common stock.
- The percentage of ownership is calculated based on 45,058,413 shares of common stock reported by the Company as outstanding as of November 1, 2024.
- Transaction details show significant sales of common stock between February 11, 2025, and February 13, 2025, at prices ranging from $3.26 to $3.65 per share.
- These sales followed earlier purchases made between December 17, 2024, and January 23, 2025, at significantly higher prices, ranging from $5.72 to $11.27 per share.
Sentiment
Score: 2
Explanation: The sentiment is negative due to a major institutional investor completely divesting its stake, especially at a significant loss compared to recent purchase prices, indicating a lack of confidence in the company's future.
Negatives
- The complete divestment by a major institutional investor like General Atlantic suggests a loss of confidence in the Company's future prospects.
- The sales were executed at prices significantly lower than the recent purchase prices, indicating a substantial realized loss for the Reporting Persons on their investment.
Risks
- The exit of a significant institutional investor may negatively impact investor sentiment and the Company's stock price.
- The implied lack of confidence from a sophisticated investor could signal underlying issues or perceived risks within Third Harmonic Bio, Inc. that were not explicitly detailed in this filing.
Future Outlook
The Reporting Persons previously stated their intention to review their investment position and potentially increase or decrease their holdings based on the Company's performance and market conditions. This filing confirms their decision to fully divest, indicating a negative outlook on their part regarding the Company's future prospects.
Industry Context
The exit of a prominent investment firm like General Atlantic from a biotechnology company such as Third Harmonic Bio, Inc. could be interpreted by the market as a signal regarding the company's specific pipeline, clinical trial progress, or broader market conditions affecting the biotech sector. It may prompt other investors to re-evaluate their positions.
Legal Proceedings
- None of the Reporting Persons or individuals listed on Schedule A have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
- None of the Reporting Persons or individuals listed on Schedule A have been a party to a civil proceeding resulting in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws, during the last five years.
Stakeholder Impact
- Shareholders: Potential negative impact on stock price due to the perceived lack of confidence from a major institutional investor and the large volume of shares sold.
- Employees: While not directly stated, a significant investor exit could indirectly affect employee morale or future strategic decisions if it signals broader company challenges.
Next Steps
- This Amendment No. 2 represents the final amendment to the Schedule 13D for the Reporting Persons, and no further filings are expected from them regarding this specific investment.
Key Dates
| Date | Description |
|---|---|
| 2021-12-17 | Date of Amended and Restated Investors' Rights Agreement. |
| 2022-08-23 | Date Investors' Rights Agreement was filed as Exhibit 4.2 to the Issuer's Registration Statement on Form S-1. |
| 2022-09-28 | Date of original Schedule 13D filing with the SEC. |
| 2024-11-01 | Date as of which 45,058,413 shares of common stock were reported outstanding by the Company. |
| 2024-11-07 | Date of the Company's Quarterly Report on Form 10-Q filing with the SEC. |
| 2024-12-17 | Trade date for purchase of 5,000 shares at $11.27. |
| 2024-12-18 | Trade date for purchase of 125,000 shares at $11.25. |
| 2024-12-19 | Trade date for purchase of 25,000 shares at $10.97. |
| 2024-12-20 | Trade date for purchase of 75,000 shares at $10.69. |
| 2024-12-30 | Trade date for purchase of 17,817 shares at $10.36. |
| 2025-01-17 | Trade date for purchase of 41,384 shares at $5.72. |
| 2025-01-21 | Trade date for purchase of 85,203 shares at $6.18. |
| 2025-01-22 | Date Amendment No. 1 to Schedule 13D was filed; trade date for purchase of 125,000 shares at $6.00. |
| 2025-01-23 | Trade date for purchase of 75,000 shares at $5.77. |
| 2025-02-11 | Date of event which requires filing of this statement; trade date for sale of 3,132,930 shares at $3.26. |
| 2025-02-12 | Trade date for sale of 56,023 shares at $3.65. |
| 2025-02-13 | Signature date of the filing; trade date for sale of 509,957 shares at $3.51. |
Recommendation
sellKeywords
Third Harmonic Bio, General Atlantic, SEC filing, Schedule 13D, beneficial ownership, divestment, exit filing, common stock, investment firm
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.